Ohio is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Observational Study Protocol: LIVER-R
NCT06252753
Recruiting
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data colle... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/21/2024
Locations: Research Site, Canton, Ohio
Conditions: Hepatobiliary Cancers
Register for Updates
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Ohio State University-Wexner Medical Center, Gahanna, Ohio
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Investigative Site US314, Cincinnati, Ohio
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: Riverhills Neuroscience - Norwood Site Number : 8400007, Cincinnati, Ohio
Conditions: Multiple Sclerosis
Register for Updates
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624
Recruiting
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treate... Read More
Gender:
All
Ages:
All
Trial Updated:
06/21/2024
Locations: University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio
Conditions: Prostate Cancer Metastatic
Register for Updates
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Remington-Davis Clinical Research, Columbus, Ohio
Conditions: NonSegmental Vitiligo
Register for Updates
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Bexley Dermatology, Bexley, Ohio
Conditions: NonSegmental Vitiligo
Register for Updates
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
NCT06099418
Recruiting
This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with chemotherapy with/without bevacizumab). The trial is designed to investigate VB10.16 alone or in combination with the immune checkpoint inhibitor, atezolizumab. The trial consist of 2 parts: the first part which investigates VB10.16 + placebo versus VB10.16 + atezolizumab. Appro... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
Register for Updates
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844
Recruiting
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
All
Ages:
70 years and above
Trial Updated:
06/21/2024
Locations: Strecker Cancer Center-Belpre, Belpre, Ohio
Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza
NCT06094010
Recruiting
The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1 to <12 years with influenza.
Gender:
All
Ages:
Between 1 year and 11 years
Trial Updated:
06/21/2024
Locations: Ohio Pediatric Research Association, Dayton, Ohio
Conditions: Influenza
Register for Updates
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
NCT06092970
Recruiting
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: Patient reported outcomes (PRO), using the EQ-5D questionnaire Clinical outcomes
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Research Site, Cleveland, Ohio
Conditions: Post-Operative Complications in Cardiac Surgery
Register for Updates
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281
Recruiting
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Gender:
All
Ages:
Between 12 years and 130 years
Trial Updated:
06/21/2024
Locations: Research Site, Columbus, Ohio
Conditions: Hypophosphatasia
Register for Updates